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Background
The GAIA Vaccine Foundation has performed three stud-
ies in Bamako Mali to evaluate baseline levels of HIV
knowledge and practices (KAP) and willingness to partic-
ipate (WTP) in an HIV vaccination trial. These studies,
performed between 2004–2008, provide a cross-sectional
perspective on KAP and WTP in an urban setting in West
Africa.
Methods
An initial study was performed at the Faculty of Medicine
(279 subjects) in 2004; a second study was performed in
the public markets of Bamako (279 subjects), in 2005,
and a third was recently performed in Sikoro, a slum
located within the city limits of Bamako, where the GAIA
Vaccine Foundation has established an HIV care center
(399 subjects). All studies were approved by the Malian
Ethical committee. Trained interviewers performed the
surveys, obtained the participants oral consent, and
recorded their knowledge of HIV, HIV transmission, HIV
prevention and willingness to participate.
Results
Overall, HIV knowledge was high, 73–93% of participants
were knowledgeable about modes of HIV transmission.
There was a high level of WTP in vaccine trials among men
and women participating in this survey. Among individu-
als surveyed in the periurban slum setting, in public mar-
kets and at the medical school, 78%, 62% and 45% were
WTP in HIV vaccine trials, respectively but WTP was
higher for malaria and tuberculosis trials. Reasons for
WTP were mixed and some participants believed that par-
ticipation in an HIV vaccine trial would protect them from
HIV.
Conclusion
In previous African KAP and WTP studies, WTP ranged
from 20% to 77%, average 47%. We observed a higher
average level of WTP (62%) among residents Bamako, but
misconceptions about reasons to participate in HIV vac-
cine trials (research vs. altruism) and vaccines in general
(do not infect recipient) will need to be addressed prior to
engaging in HIV vaccine trials in this region of West Africa.
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